CASB.F Stock Overview
Develops, manufactures, and commercializes vaccines in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CanSino Biologics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$3.90 |
| 52 Week High | HK$4.23 |
| 52 Week Low | HK$1.86 |
| Beta | 0.49 |
| 11 Month Change | 11.11% |
| 3 Month Change | 96.97% |
| 1 Year Change | 9.86% |
| 33 Year Change | -81.40% |
| 5 Year Change | n/a |
| Change since IPO | -48.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| CASB.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.4% | 2.2% |
| 1Y | 9.9% | 16.2% | 31.7% |
Return vs Industry: CASB.F underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: CASB.F underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| CASB.F volatility | |
|---|---|
| CASB.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CASB.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine CASB.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1,149 | Xuefeng Yu | www.cansinotech.com |
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination.
CanSino Biologics Inc. Fundamentals Summary
| CASB.F fundamental statistics | |
|---|---|
| Market cap | US$1.56b |
| Earnings (TTM) | -US$99.35m |
| Revenue (TTM) | US$103.27m |
8.3x
P/S Ratio-8.6x
P/E RatioIs CASB.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CASB.F income statement (TTM) | |
|---|---|
| Revenue | CN¥748.53m |
| Cost of Revenue | CN¥774.40m |
| Gross Profit | -CN¥25.87m |
| Other Expenses | CN¥694.25m |
| Earnings | -CN¥720.11m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Nov 25, 2024
| Earnings per share (EPS) | -2.91 |
| Gross Margin | -3.46% |
| Net Profit Margin | -96.20% |
| Debt/Equity Ratio | 41.3% |
How did CASB.F perform over the long term?
See historical performance and comparison